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Abstract
Tumor targeting by genetically modified mesenchymal stromal/stem cells (MSCs) carrying anti-cancer molecules represents
a promising cell-based strategy. We previously showed that the pro-apoptotic agent tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) can be successfully delivered by MSCs to cancer sites. While the interaction between TRAIL and
its receptors is clear, more obscure is the way in which MSCs can selectively target tumors and their antigens. Several
neuroectoderm-derived neoplasms, including glioblastoma (GBM), sarcomas, and neuroblastoma, express high levels of the
tumor-associated antigen GD2. We have already challenged this cell surface disialoganglioside by a chimeric antigen
receptor (CAR)-T cell approach against neuroblastoma. With the intent to maximize the therapeutic profile of MSCs
delivering TRAIL, we here originally developed a bi-functional strategy where TRAIL is delivered by MSCs that are also
gene modified with the truncated form of the anti-GD2 CAR (GD2 tCAR) to mediate an immunoselective recognition of
GD2-positive tumors. These bi-functional MSCs expressed high levels of TRAIL and GD2 tCAR associated with a robust
anti-tumor activity against GD2-positive GBM cells. Most importantly, the anti-cancer action was reinforced by the
enhanced targeting potential of such bi-functional cells. Collectively, our results suggest that a truncated anti-GD2 CAR
might be a powerful new tool to redirect MSCs carrying TRAIL against GD2-expressing tumors. This affinity-based dual
targeting holds the promise to combine site-specific and prolonged retention of MSCs in GD2-expressing tumors, thereby
providing a more effective delivery of TRAIL for still incurable cancers.
INTRODUCTION
Human mesenchymal stromal/stem cells (MSCs) are con-
sidered pivotal players in cellular therapy. Their isolation
easiness from different sources and their capacity to be
engineered by viral vectors make them cellular vehicles to
deliver anti-tumor agents [1]. As putative tumor stroma cell
precursors, MSCs can localize within tumors by promising
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but still unclear mechanisms of action [2]. A homing ability
of MSCs has been reported towards several cancers
including glioma, breast, colon, ovarian, pancreatic, and
lung carcinomas, among many other tumors. Once to the
tumor site, they can offer a prolonged and concentrated
local delivery of therapeutic molecules, reducing a non-
selective targeting to possibly improve efficacy of standard
treatments [3].
Glioblastoma (GBM) is the most common primary
malignant brain tumor in human. Despite considerable
advances in therapies, GBM remains one of the most
challenging diseases [4]. The invasive nature of GBM is the
major reason underlying failure of surgical resection alone
or in association with standard radiation and temozolomide-
based chemotherapy [5]. Novel strategies based on onco-
lytic viral vectors have difficulties in reaching metastatic
niches from the main tumor burden [6, 7].
New effective tools are needed to specifically target
cancer cells within a context characterized by a high local
metastatic potential [8]. It has been demonstrated that MSCs
can be primarily attracted by GBM while sparing healthy
brain in such a way to become a tumor-specific drug
delivery system [9]. Recently, few strategies have been
envisioned to attain an effective and localized MSCs
delivery to GBM extending the therapeutic effect and lim-
iting off-target toxicities [10–12]. Despite MSCs tropism for
tumor microenvironment, the engraftment and retention of
MSCs in tumor still remains an issue to be addressed [13].
Therefore, parallel to homing, particular attention is
needed on how to improve MSC affinity for the tumor site
in order to achieve tumor-specific targeting and retention
[14]. Much of the groundwork for affinity-based targeting
approaches has been established in the field of viral gene
delivery and in adoptive immunotherapy. The highest
binding abilities have been obtained using antibodies, TCR,
and chimeric antigen receptor (CAR) [15].
This targeting takes advantage of surface molecules
uniquely or highly expressed by tumor cells. Regarding
GBM, it has been demonstrated that a variety of GBM lines
and primary biopsies commonly express high levels of
disialoganglioside GD2 antigen, similarly to several pedia-
tric and adult cancers [16, 17]. GD2 levels increase in GBM
compared to the surrounding normal brain, being a rela-
tively minor component of the normal central nervous
system (<4% of total gangliosides). For this reason, GD2
becomes an attractive clinical target for GBM and other
brain tumors [16].
In recent years, our group developed T cells expressing
anti-GD2 CAR [18]. CAR affinity domain, represented by
the single-chain variable fragment (scFv) of an immu-
noglobulin against a specific tumor marker, redirects the
killing functions of immune cells to the defined target upon
recognition, thereby enhancing the retention to the tumor
site [19]. In a parallel project, adipose (AD)-MSCs were
modified by viral vectors in order to constantly express a
variant of the potent anti-tumor ligand tumor necrosis
factor-related apoptosis inducing ligand (TRAIL) allowing
a local effective killing in a variety of cancers [20–23].
Taking inspiration from CAR T cells as successful
examples for the specific recognition and binding to target
cells, we originally further optimized tumor-localizing
potential of TRAIL-expressing MSCs. Thus, we combined
anti-GD2-targeted strategy where TRAIL is expressed on
AD-MSCs together with a truncated form of a previously
developed anti-GD2 CAR (GD2 tCAR) [18]. This GD2
tCAR lacks the intracellular signaling domain while pre-
serving the transmembrane region and the extracellular anti-
GD2 binding moiety. Owing to this immunoselective GD2-
based targeting, MSCs carrying TRAIL have been specifi-
cally redirected towards GD2-expressing tumors while
improving cell-to-cell interaction. To the best of our
knowledge, this study is the first report on the genetic
modification of therapeutic TRAIL MSCs to express an
artificial receptor (AR) against GD2. TRAIL MSCs killing
function coupled with GD2 tCAR affinity-based tumor
targeting could be advantageous to improve therapeutic
delivery of TRAIL molecule for the treatment of still deadly
GD2-positive malignancies.
Materials and methods
Cell culture and maintenance
Human GBM cell lines T98G, U87MG, and A172 are a
kind gift from Dr. Franco Bambi (Meyer Children’s Hos-
pital, Florence, Italy). The primary C3c GBM cell line was
obtained from a patient affected by GBM (female, IV grade)
and collected at the Department of Neurosurgery, Nuovo
Ospedale Civile S. Agostino Estense, Modena, Italy. Tissue
procurement was approved by the local Ethical Committee
(#3600/27 September 2017). T98G and U87MG cell lines
were cultivated in minimum essential medium (MEM)
Eagle's with Earle's salts (Euroclone, Milan, Italy). A172
were maintained in Dulbecco’s modified Eagle's medium
(DMEM; Gibco, Thermo Fisher Scientific, Waltham, MA,
USA). The primary C3c GBM cell line was kept in DMEM/
F-12 (Gibco). Media were supplemented with 10% fetal
bovine serum (Carlo Erba Reagents Srl, Cornaredo, Italy),
1% L-glutamine (200 mM) (BioWhittaker, Lonza, Verviers,
Belgium), and 1% penicillin–streptomycin (pen/strep; 104
UI/ml and 10 mg/ml; Carlo Erba Reagents Srl). Human
AD-MSCs were obtained as previously described [20].
After isolation, cells were grown in α-MEM (Gibco) con-
taining 2.5% platelet lysate (Modena Policlinic Blood
Bank, Modena, Italy), 1% L-glutamine, 0.5%
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ciprofloxacin (Fresenius Kabi Italia srl, Verona, Italy), and
0.2% heparin (Sigma-Aldrich, Saint Louis, MO, USA).
Cells were incubated and maintained within a controlled
atmosphere, 5% CO2, and temperature of 37 °C. Authenti-
cation of T98G, U87MG, and A172 cell lines has been
recently performed by the Leibniz Institute DSMZ - Ger-
man Collection of Microorganisms and Cell Cultures
GmbH, Braunschweig, Germany.
Viral vectors and AD-MSC transduction
We recently generated a CAR able to bind the dis-
ialoganglioside GD2 for an immunotherapy approach
against GD2-expressing cancers [18]. A truncated form of
that CAR lacking the signaling domains 4-1BB (CD137)
and CD3-ζ has been introduced into AD-MSCs (Fig. 1a,
row 1). Truncated anti-GD2 CAR (GD2 tCAR) gene is
composed by an anti-GD2 scFv from a murine antibody of
immunoglobulin M (IgM) class linked to a portion of CD8,
the CD8α hinge-transmembrane domain. The GD2 tCAR
expression cassette was cloned into the multiple cloning site
of the lentiviral vector pCCL PGK WPRE, using BamHI
and SalI restriction enzymes. Properly sequenced full-
length human TRAIL gene has been cloned (XmaI/SalI)
into the lentiviral vector pCCL PGK WPRE to gene modify
AD-MSCs for the surface expression of membrane-bound
TRAIL (mTRAIL) molecule (Fig. 1a, row 2). AD‐MSC
transductions were performed as previously reported [23].
The transduced AD-MSC lines were defined as empty
vector (EV MSCs), GD2 tCAR vector (GD2 tCAR MSCs),
Fig. 1 MSCs are effectively
transduced with GD2 tCAR and/
or TRAIL encoding vectors. a
Schematic presentation of the
GD2 tCAR expression construct
(upper) in which the IgM-
derived anti-GD2 scFv was
fused with the human CD8α-
derived hinge-transmembrane
domain and cloned between
PGK and WPRE lentiviral
regulatory elements, the
mTRAIL expression construct
(lower) carrying the full-length
human TRAIL gene between
PGK and WPRE. b FACS
analysis of TRAIL and GD2
tCAR expression on empty
vector-transduced MSCs, EV
MSCs (row 1), GD2 tCAR
MSCs transduced with GD2
tCAR vector (row 2), mTRAIL
MSCs transduced with vector
coding for mTRAIL (row 3),
and bi-functional MSCs coding
for both GD2 tCAR and
mTRAIL (row 4)
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vector carrying mTRAIL alone (mTRAIL MSCs) and bi-
functional MSCs coding for both GD2 tCAR and mTRAIL.
Fluorescence-activated cell sorting
TRAIL presence on AD-MSCs was assayed by a phy-
coerythrin (PE)-conjugated anti-TRAIL antibody (BioLe-
gend, San Diego, CA, USA). Intracellular staining on
transduced MSCs was performed with Becton Dickinson
Cytofix/Cytoperm Kit (BD, Franklin Lakes, NJ, USA). To
detect GD2 tCAR expression on AD-MSCs, anti-idiotypic
antibodies were raised as previously described [18, 24].
AD-MSCs were incubated with anti-idiotype mice sera
followed by allophycocyanin (APC)-conjugated goat anti-
mouse secondary antibody (BD). TRAIL receptors expres-
sion on GBM cell lines was tested by fluorescence-activated
cell sorter (FACS), as well. Tumor cell lines were stained by
PE-conjugated anti-TRAIL-R1/DR4 and anti-TRAIL-R3/
DcR1, and APC-conjugated anti-TRAIL-R2/DR5 and anti-
TRAIL-R4/DcR2 (BioLegend). To evaluate GD2 antigen
expression, tumor cell lines were stained with primary
unconjugated mouse anti-human GD2 (BD) and then with
APC goat anti-mouse Ig (APC Goat Anti-Mouse Ig poly-
clonal multiple adsorption; BD). In all the experiments,
corresponding isotype-matched antibodies were used as
negative controls (provided by BD and BioLegend). Data
were collected using FACS Aria III flow cytometer (BD)
and analyzed using the FACS Diva software (BD).
Dose–response rhTRAIL
Tumor cell lines were seeded in 96-well cell culture plate at
6000 cells/cm2. After 12 h, different concentrations (10 ng,
50 ng, 100 ng, 500 ng, and 1000 ng/ml) of recombinant
human TRAIL (rhTRAIL) (Peprotech, London, UK) were
added in the culture media. Proliferation rate was assessed
after 24 h by the colorimetric assay CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Madison,
WI, USA). Alternatively, tumoricidal activity of rhTRAIL
was evaluated by supravital propidium iodide (PI; Sigma-
Aldrich) staining after 24 h by FACS.
Cytotoxicity assays
Tumor cell lines were seeded in 12-well cell culture plate at
6000 cells/cm2. After 12 h, all gene-modified MSCs were
labeled with carboxyfluorescein succinimidyl ester (CFSE)
cell tracker (Molecular Probes, Eugene, OR, USA) and
added at different target-to-effector (T:E) ratios (1:1, 1:2,
and 1:5). The tumoricidal activity of MSC-expressing
TRAIL was evaluated by PI or Annexin V (BD)/PI stain-
ing after 12, 24, and 48 h by FACS gating on CFSE-
negative cells and PI-positive or Annexin V/PI-double-
positive events. Soluble rhTRAIL at 1 μg/ml was introduced
as a positive control.
Cell-to-cell interaction assays
The cell-to-cell interaction assay was established by the
selective target cell recognition mediated by GD2 tCAR-
functionalized MSCs against GBM cell lines that markedly
differ for GD2 expression levels. A monocistronic murine
stem cell virus-derived retroviral vector encoding for the red
fluorescent protein DsRed was used to stably transduce
GBM cell lines (T98G, U87MG, and A172) and to distin-
guish them from MSCs into the cell-to-cell interaction
assay. Retrovirus production was performed by FLYRD18
packaging cell line, as published [20]. The primary C3c
GBM line was labeled by CellTracker Deep Red Dye
(Thermo Fisher Scientific).
Similarly, MSCs were labeled with the CFSE fluorescent
dye according to the reagent’s manual. A cell-to-cell
interaction assay was performed as described. CFSE-
labeled MSCs were seeded into a 12-well cell culture
plate at a high density (100,000 cells/well) to create a
confluent monolayer in 12 h. To test cell-to-cell interac-
tions, a suspension of DsRed (or Deep Red for primary C3c
GBM) tumor cells (70,000 cells per well) were added to the
MSC monolayer. After 1 h and half incubation time,
media were removed and the coculture were washed
twice in phosphate-buffered saine (PBS) and shaken for
3 min in order to lose weakly adherent tumor cells.
An incubation time of 20 min has been identified as
optimal for the primary C3c GBM line, as this line has a
greater basal adherence to MSCs in comparison to that of
GBM lines. The cells were then collected by trypsinization
and suspended in a constant volume of PBS. The absolute
number of MSC–tumor cell aggregates was quantified by
FACS considering the CFSE/DsRed (or CFSE/Deep Red)-
double-positive population in a constant time frame of 60 s.
Data were expressed comparing the number of MSC–tumor
cell aggregates acquired for all the conditions versus EV
MSCs.
A cell-to-cell interaction cytotoxicity assay was further
challenged to detect the bi-functional MSC-specific cyto-
toxic effect against GD2-positive GBM cells at an early
time point of 7 h incubation. The early cell death in MSC-
GBM cell aggregates was evaluated by Annexin V staining
and FACS analysis gating on CFSE/DsRed-double-positive
conglomerates recording a fixed number of events, for all
the conditions. Data were expressed as the percentage of
Annexin V-positive MSC-GBM cell aggregates. Anti-
idiotype mice sera against GD2 tCAR were further used
to block the GD2 tCAR-mediated interaction between bi-
functional MSCs and GD2-expressing GBM cells and the
effect on apoptosis was investigated. Briefly, MSCs
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were incubated with a 1:20 dilution of mice sera for 40 min
at 37 °C, 5% CO2, and then used to set up a cell-to-cell
interaction assay as described above. The percentage of
Annexin V-positive MSC-GBM cell aggregates at a 7 h
incubation was analyzed by FACS.
Statistics
Analyses were performed using Excel 2016 program
(Microsoft Inc., Redmond, WA, USA). Data are expressed
as mean ± SD. A p value of ≤ .05 from two-tailed Student’s
t test was considered statistically significant. Normal dis-
tribution of data has been tested using Shapiro–Wilk nor-
mality test. For the assays, each experimental group was
assayed at least twice in triplicate.
Results
Engineered bi-functional MSCs express GD2 tCAR
and deliver TRAIL
Co-expression of GD2 tCAR together with mTRAIL in
MSCs was obtained by lentiviral vector transduction. The
presence of mTRAIL and GD2 tCAR molecules was ver-
ified by FACS on transduced MSCs (Fig. 1b). TRAIL and
GD2 tCAR were undetectable on EV MSCs (Fig. 1b, row
1), while GD2 tCAR was exclusively revealed in 79 ± 7%
of GD2 tCAR MSCs (Fig. 1b, row 2). As expected, TRAIL
presence was confirmed on 95 ± 8% of mTRAIL MSCs (55
± 7% on cell membrane and 40 ± 15% in the cytoplasm;
Fig. 1b, row 3). Bi-functional MSCs expressed TRAIL
together with the GD2 tCAR. In particular, TRAIL was
detected in 71 ± 4% of bi-functional MSCs (49 ± 7% on cell
membrane and 22 ± 3% in cytoplasm), and 65 ± 17% of bi-
functional MSCs were also positive for GD2 tCAR (Fig. 1b,
row 4). These findings demonstrate that high levels of GD2
tCAR on bi-functional MSCs do not affect TRAIL pro-
duction, underlining the feasibility of our dual-targeting
approach.
GBM cells differentially express GD2, have high
expression of TRAIL receptor DR5, and are sensitive
to rhTRAIL
Having generated the effectors, in order to challenge
our cell therapy approach against three different GBM
cell lines, we began testing both GD2 and TRAIL
receptors, as predictive factor for affinity-based targeting
and TRAIL sensitivity. FACS analyses revealed that the
three selected GBM cell lines differ for GD2 expression
(Fig. 2a). Specifically, we could distinguish GBM cell
lines in the GD2 highly positive T98G (97 ± 1%), the
GD2 middle-positive U87MG (57 ± 13%), and the GD2-
negative A172 (2 ± 1%). Similarly to T98G, the primary
C3c GBM line expressed high levels of GD2 (97%;
not shown).
On TRAIL receptors expression (Fig. 2b), FACS ana-
lyses revealed high levels of DR5 (≥95%) and negligible
expression of DR4 for all lines. Decoy receptor DcR1 was
undetectable in all cell lines (<2%), whereas DcR2 was
positive for U87MG (28 ± 8%) with very low presence on
A172 (2 ± 1%) and negative for T98G (0.5 ± 0.5%). In
addition, the primary C3c GBM line highly expressed the
DR5 (89%), while it was negative for DR4 (0.1%), DcR1
(0.1%), and DcR2 (1.9%) (not shown). Dose–response tests
were introduced to verify rhTRAIL sensitivity on GBM cell
lines (Fig. 2c). Despite similar levels of DR5, GBM lines
demonstrated differences in rhTRAIL responsiveness with
A172 being the most sensitive (33 ± 0.02% cell viability;
p < .05) and U87MG the lowest one (67 ± 0.02% cell
viability; p < .05), after 24 h at the highest rhTRAIL dose
(1 μg/ml).
Bi-functional MSCs induce in vitro apoptosis in GBM
cells
Having proved the sensitivity of GBM lines to TRAIL pro-
apoptotic effect, we performed cocultures to verify the
effectiveness of our cell therapy strategy based on genetically
modified bi-functional MSC-expressing mTRAIL and GD2
tCAR. The killing potential mediated by bi-functional MSCs
was assessed testing different time points (24 and 48 h) and
multiple target to effector ratios (1:1, 1:2, and 1:5 T:E
ratios; Fig. 3). The green fluorescence of CFSE-labeled
MSCs allowed a clear distinction between target (CFSE-
negative) and effector cells (CFSE-positive) by FACS.
Gating on CFSE-negative and PI-positive tumor cells, we
were able to specifically quantify the percentage of tumor
cell death. The bi-functional MSCs cytotoxic effect was
also challenged comparing the impact induced by rhTRAIL
(1 μg/ml) or mTRAIL MSCs, whereas EV MSCs and GD2
tCAR MSCs were used as negative controls. Starting from
24 h, all tested GBM cell lines displayed a significant sen-
sitivity to TRAIL delivered by MSCs (Fig. 3, left column).
A172 appeared to be the most sensitive line (up to 73 ± 8%
cell death, with the highest mTRAIL MSC dose; Fig. 3c,
left column), whereas U87MG appeared to be less sensitive
to both rhTRAIL and mTRAIL MSCs (32 ± 5% and 41 ±
8% cell death, respectively; Fig. 3b, left column). At 1:5
ratio, bi-functional MSCs were able to exert a robust
cytotoxic effect in T98G and A172 lines (50 ± 4% and 67 ±
6% cell death respectively, p < .001), provoking a mortality
rate comparable to mTRAIL MSCs or rhTRAIL (p > .05,
Fig. 3a, c, respectively, left column). The cytotoxicity
mediated by bi-functional MSCs increased according
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to the T:E ratios for T98G and A172 GBM lines at 24 h
(p < .05). The GBM cell apoptosis by bi-functional MSCs
was further confirmed at 48 h (Fig. 3, right column) with a
similar trend of the 24 h. Once again, T98G and A172
lines appeared to be particularly responsive to both
mTRAIL MSCs and bi-functional MSCs (p < .05; Fig. 3a,
c, respectively, right column). In particular, at 48 h bi-
functional MSCs were able to induce tumor cell death in
T98G (55 ± 6%) and A172 lines (57 ± 5%) with levels that
remained stable regardless of effectors number, unlike to
what observed at 24 h (p > .05). For all tested culture
conditions and time points, cocultures of GBM cell lines
with EV MSCs or GD2 tCAR MSCs did not impact tumor
cell survival.
Fig. 2 GBM target cells
characterization. a
Representative histograms
showing GD2 expression, dark
gray curve, on human T98G (97
± 1%), U87MG (57 ± 13%), and
A172 (2 ± 1%) GBM cell lines
by FACS. APC-conjugated
secondary Ab was used as
isotype and represented by light
gray line. b Expression of both
agonistic (DR4 and DR5) and
decoy (DcR1, DcR2) TRAIL
receptors on GBM cell lines by
FACS. c Sensitivity of GBM
tumor cells to apoptosis induced
by recombinant human TRAIL
(rhTRAIL). T98G cell viability
by supravital propidium
iodide (PI) staining, U87MG
and A172 cell viability by MTS
assay after 24 h of rhTRAIL
treatment at different doses in
comparison with untreated
control (CTR). p < .05 by
Student’s t test between the
highest rhTRAIL dose (1000 ng/
ml) and untreated CTR, for all
GBM lines. Data are expressed
as mean ± SD
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The killing by bi-functional MSCs was further chal-
lenged against the primary C3c GBM line (Fig. 3d). Bi-
functional MSCs were able to exert a cytotoxic effect,
provoking the highest tumor mortality (44 ± 4%) at 1:5 T:E
ratio at 48 h, comparable to mTRAIL MSCs (p > .05).
Similarly to what observed for cell lines, EV MSC or GD2
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tCAR MSC cocultures did not impact cell survival on pri-
mary C3c cells.
These in vitro data outline a significant, although vari-
able, sensitivity of GBM towards MSCs delivering TRAIL.
In particular, we demonstrated that the simultaneous
expression of pro-apoptotic TRAIL ligand and GD2 tCAR
does not affect the killing by engineered MSC, thus
prompting our dual-targeting approach against GD2-
postitive GBM.
GD2 tCAR functionalization improves the interaction
with GD2-expressing GBM cells
We hypothesized that MSCs surface functionalization with
the GD2 tCAR is able to force interaction between MSCs
and GBM cells expressing GD2. To investigate the new
properties acquired by bi-functional MSC, we tested their
ability to bind GBM in a cell-to-cell interaction assay. For
this purpose, MSCs were labeled by CFSE, to acquire a
green fluorescence; conversely, GBM cell lines were stably
infected with viral vector coding for DsRed gene to exhibit
a red fluorescence, while the primary C3c GBM line was
labeled by the CellTracker Deep Red dye.
By these different labeling strategies, MSCs and GBM
cells were clearly distinguishable by FACS and their
aggregates appeared as double positive for both CFSE and
DsRed (or Deep Red) fluorescence. In a cell-to-cell inter-
action assay GBM cells were added to CFSE-labeled MSC
monolayers and left in interaction for 1.5 h (or 20 min for
primary C3c cells).
After sequential washing to lose weakly interactors, cells
were collected by trypsinization and analyzed by FACS to
determine the absolute number of MSC-GBM cell aggre-
gates, visualized as CFSE/DsRed (or CFSE/Deep Red)
double-positive events. The related gating strategy is
described in Fig. 4a. Cells were first gated on forward
scatter area (FSC) and side scatter area (SSC) to exclude
debris (P1), then DsRed (or Deep Red)-GBM cells (in red;
P2) and CFSE-MSCs (in green; P3) were visualized in a
CFSE/DsRed (or CFSE/Deep Red) dot plot to finally
gate the double-positive events, corresponding to the
MSC-GBM cellular aggregates and represented as yellow
dots in the upper right quadrant (P4). A backgate of CFSE/
DsRed (or CFSE/Deep Red) double-positive population in
P1 confirmed the greater size and complexity of MSC-GBM
cells conglomerates. The number of aggregates generated
by cell-to-cell interaction of GBM cells with either GD2
tCAR MSCs, or bi-functional MSCs or mTRAIL MSCs
were normalized to EV MSC-GBM cell aggregate numbers
and data displayed as fold, for all GBM lines tested
(Fig. 4b). Very interestingly, the fold strictly correlated with
both GD2-aboundance on GBM cell lines and the MSCs
capability to interact via GD2 tCAR surface expression.
GD2 tCAR MSCs and bi-functional MSCs bound the
highly GD2-positive T98G line at least four times more
than EV MSCs and mTRAIL MSCs (p < .001; Fig. 4b). A
lower but significant binding gain of GD2 tCAR MSCs and
bi-functional MSCs was found for U87MG GD2-
intermediate line (p < .01; Fig. 4c). As for the A172 GD2-
negative line, no differences in aggregate formation were
detected among MSC groups, as this tumor cell line does
not express GD2 ligand (Fig. 4d). As a further confirmation,
GD2 tCAR MSCs and bi-functional MSCs led to a greater
binding to primary C3c GBM line in comparison to EV
MSCs and mTRAIL MSCs (p < .05; Fig. 4e). Collectively,
these findings indicate that MSCs functionalized by an anti-
GD2 AR gain an increased and specific binding to GBM
cells expressing different levels of GD2.
Co-expression of mTRAIL and GD2 tCAR confers to
bi-functional MSCs a rapid killing activity against
GD2-positive GBM cells
A cell-to-cell interaction cytotoxicity assay was performed
to address whether the enhanced binding ability of bi-
functional MSCs to GD2-positive GBM cells would trans-
late into a more effective killing compared to mTRAIL
MSCs. Cell death was evaluated at early time point (7 h) by
Annexin V on CFSE/DsRed double-positive aggregates. A
gating strategy (Fig. 5a) was applied also to this experi-
mental setting and the percentage of Annexin V-positive
MSC-GBM cell aggregates (P4) was quantified. To confirm
the GD2 tCAR role in leading a more rapid apoptosis
mediated by bi-functional MSCs, anti-idiotype mice sera
against the GD2 tCAR were used to block the binding
between GD2 ligand and GD2 tCAR (Fig. 5b). Interaction
between bi-functional MSCs and GBM cells produced a
significant apoptotic effect on cell aggregates (59 ± 5%),
compared to both mTRAIL MSCs (32 ± 7%; p < .001) and
non-expressing TRAIL ones, EV MSCs and GD2 tCAR
MSCs (9 ± 3% and 15 ± 4%, respectively, p < .001; Fig. 5b,
smooth columns).
Fig. 3 Bi-functional MSCs exert in vitro cytotoxicity on target GBM
cell lines. a In vitro impact of bi-functional MSCs against a T98G,
b U87MG, c A172 GBM lines, and d primary C3c GBM cells testing
multiple target-to-effector ratios (1:1, 1:2, and 1:5). Tumor cell death
by supravital propidium iodide (PI) for T98G, A172, and C3c and by
Annexin V/PI staining for U87MG after 24 h (left column) and 48 h
(right column). Recombinant human TRAIL (rhTRAIL, 1μg/ml) was
used as a positive control of cell death, while tumor cell lines alone as
a negative control (CTR). Reported p values regard multiple com-
parisons among mTRAIL MSCs and bi-functional MSC conditions
versus control groups represented by EV MSCs, GD2 tCAR MSCs,
rhTRAIL, or CTR. For T98G, *p < .05, °p < .01, §p < .01; for U87MG,
*p < .05, °p < .05, §p < .05; for A172, *p < .05, °p < .01, §p < .05; for
C3c, *p < .05, °p < .001, §p < .00. All p values have been calculated by
Student’s t test. Data are expressed as mean ± SD
G. Golinelli et al.
Blocking the GD2-mediated interaction by anti-
idiotype sera incubation [18, 24], bi-functional MSCs
significantly reduced the percentage of Annexin
V-positive aggregates (40 ± 2%), comparable to mTRAIL
MSCs with (36 ± 7%) or without sera incubation (32 ±
7%; p > .05; Fig. 5b, striped columns). These data suggest
that GD2 tCAR expression on bi-functional MSCs allows
a specific targeting to GD2-expressing GBM potentiating
the cytotoxic effect.
Discussion
We have here explored how engineered human MSCs by a
truncated IgM-derived anti-GD2 CAR can be a powerful
new tool to specifically redirect MSCs delivering TRAIL
against a GD2-expressing tumor, such as GBM. The inva-
sive nature of GBM is still the major reason for failure in
surgical resection and after standard therapeutic approaches
[5]. The tumor-tropic ability of MSCs offers an alternative
where these cells can be used as vehicle of anti-tumor
molecules delivery to modify tumor microenvironment and
destroy cancer from inside, the so-called “Trojan horse
effect” [1]. MSCs can home and persist into the tumor
inflammatory stroma arranging themselves in close
proximity with tumor cells and neovasculature [14]. Among
anti-cancer drugs deliverable by MSCs there is the protein
known as TRAIL. To date, multiple attempts to use MSCs
as TRAIL-vehicle against GBM have been described [25,
26]. However, even though MSCs tropism for tumors has
been confirmed in a variety of experimental models, there is
no evidence of an efficient and long-term engraftment of
MSCs, highlighting that inherent MSCs homing and
retention capabilities into the tissue of interest might be
insufficient for solid therapeutic benefit [27]. Efforts should
be therefore directed towards optimization of both efficacy
and specificity of MSC-based therapy targeting a specific
cell population and prolonging MSCs retention. While these
tasks are challenging, MSC cancer-targeting strategies may
be employed to enhance the efficiency in reaching out
tumors and consequently increase the bioavailability of the
therapeutics. These may include physical cell routing, uti-
lization of physiological forces for cell concentration, and
strategies that involve engineering cell homing/targeting
machinery [15].
By multiple in vitro assays, we explored whether the
native tumor tropism of MSCs can be enhanced by engi-
neered targeting via expression of a tumor-binding AR.
First, we investigated the feasibility of expressing the GD2
tCAR on the cell surface of adipose MSCs by lentiviral
Fig. 4 GD2 tCAR on MSCs surface increases binding to GD2-
expressing GBM cells in vitro by a cell-to-cell interaction assay.
a Gating strategy for the analysis of the absolute number of MSC-
GBM cell aggregates after 1.5 h incubation time. Gate 1: forward
scatter area (FSC) and side scatter area (SSC) were used to enrich for
intact cells (P1). Gate 2: CFSE staining (P3) and DsRed (or Deep Red)
fluorescence (P2) recorded in the logarithmic scale were used to
identify MSC-GBM cell aggregates appeared to be CFSE/DsRed (or
CFSE/Deep Red) double positive (P4). Backgating in P1 population to
identify MSC-GBM cell aggregates by morphological parameters. To
quantify the absolute number of aggregates, for all tested conditions,
we considered the number of cellular events acquired into the CFSE/
DsRed (or CFSE/Deep Red) double-positive gate (P4) over 60 s. b–e
Number of MSC-GBM cell aggregates reported as fold of all condi-
tions versus EV MSCs, for all GBM cell lines and primary C3c GBM
cells. GD2 tCAR MSCs and bi-functional MSC bound GD2-positive
cells, T98G (b), U87MG (c), and C3c (e) greater than EV MSCs
and mTRAIL MSCs (*,°p < .05). For A172 negative line (d), no dif-
ferences in aggregates formation were found between the MSC types.
*,°p < .05 by Student’s t test. Data are expressed as mean ± SD
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transduction, in order to specifically target GD2-expressing
tumor cells. The transduction of AD-MSCs with the vector
encoding for GD2 tCAR was very efficient and did not
interfere with the simultaneous expression of TRAIL.
Previous works gave evidences of MSCs localization
into glioma after systemic delivery or local intracranial
injection followed by migration towards GBM [28, 29].
Once there, MSCs can also effectively deliver therapeutic
proteins with a pre-clinical efficacy [6, 25, 26]. As reported,
GBM represents one of the most GD2-positive solid tumor
[16, 17, 30], suggesting that an anti-GD2-immunotargeted
MSC-based strategy may further enhance their therapeutic
profile.
Considering this MSCs tropism for brain tumors, we
hypothesized that strengthening adherence to tumor cells
by GD2 tCAR could enhance bi-functional MSCs reten-
tion within GD2-positive GBM tumor bed while poten-
tially sparing the normal brain tissue. This in turn may
affect the efficacy of our cell-based approach, as pre-
requisite for a local delivery of bi-functional MSCs into
GBM site (Fig. 6). Three different GBM cell lines were
considered. GBM lines were first characterized in terms of
GD2 antigen expression, as predictive factor for affinity-
based targeting. Based on GD2 antigen abundance on the
surface, we distinguished a GD2 highly-positive (T98G),
a GD2-middle positive (U87MG), and a GD2-negative
cell line (A172). We also considered a primary GBM
sample providing evidence of a relevant GD2 expression,
as previously reported [17].
All tested GBM cell lines were highly positive for the
agonistic receptor DR5, implying a possible responsiveness
to TRAIL apoptotic effect and did not express DcR1 and
DcR2, exception made for U87MG where intermediate
levels of DcR2 were detected, as previously described by
Röhn et al. [31]. For instance, the primary C3c GBM line
expressed high levels of DR5, whereas DR4 and both decoy
receptors were undetectable. A dose-dependent effect of
rhTRAIL protein was tested to confirm their sensitivity. As
expected, rhTRAIL induced apoptosis in both T98G and
A172, in a dose-dependent manner, whereas U87MG cells
Fig. 5 Bi-functional MSCs exert specific in vitro cytotoxicity at an
early time point against T98G GBM cell line by a cell-to-cell inter-
action cytotoxicity assay. a Gating strategy applied to quantify the
percentage (%) of Annexin V-positive MSC-GBM cell aggregates
after 7 h incubation time. Gate 1: forward scatter (FSC) and side scatter
(SSC) were used to enrich for intact cells (P1). Gate 2: CFSE staining
(P3) and DsRed fluorescence (P2) recorded in the logarithmic scale
were used to identify MSC-GBM cell aggregates visualized as CFSE/
DsRed double positive (P4). Backgating in P1 population to
identify MSC-GBM cell aggregates by morphological parameters.
Early cell death in MSC-GBM cell aggregates was evaluated by
Annexin V (APC) by FACS gating on CFSE/DsRed-double-positive
conglomerates while recording a fixed number of events for all con-
ditions. b Interaction between bi-functional MSCs and GBM cells
(smooth columns) produced a significant apoptotic effect on cell
aggregates (59 ± 5%), compared to both mTRAIL MSCs (32 ± 7%)
and non-expressing TRAIL ones, EV MSCs (9 ± 3%) and GD2 tCAR
MSCs (15 ± 4%) (*p < .001). Blocking GD2 antigen–GD2 tCAR
binding by anti-idiotype sera incubation (striped columns), sig-
nificantly reduced the percentage of Annexin V-positive aggregates
(40 ± 2%), comparable to mTRAlL MSCs with (36 ± 7%) or without
(32 ± 7%) sera incubation. *p < .001, **p < .001, °p < .001, and
°°p < .001 by Student’s t test. Data are expressed as mean ± SD
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resulted less sensitive to apoptotic effect performed by
rhTRAIL.
Looking at first to cytotoxicity, bi-functional MSCs
effectively killed all GBM lines in coculture assay; how-
ever, the effect was stronger against T98G and A172 than
U87MG line. We assume that the lower sensitivity dis-
played by U87MG could be due to different molecular
mechanisms impacting on the TRAIL pathway which need
to be better investigated. For instance, a study by Qiu et al.
[32] indicates that paclitaxel, a member of a class of anti-
cancer drugs known as taxanes, can sensitize U87MG cells
to TRAIL by upregulating DR4, caspase-8 and caspase-3.
Our group, in the attempt to overcome the U87MG partial
resistance towards TRAIL-induced cell death, recently
sensitized U87MG line by paclitaxel treatment, reaching
successful levels of apoptosis by mTRAIL MSCs (not
shown). In addition, bi-functional MSCs proved to be
effective also against the primary C3c line, further con-
firming that the simultaneous expression of pro-apoptotic
TRAIL ligand and GD2 tCAR protein does not affect the
killing by bi-functional MSCs.
In parallel to the assessment of cytotoxicity, we inves-
tigated whether the GD2 tCAR was capable to improve
MSCs affinity for GBM, hence extending TRAIL-mediated
therapeutic effect and limiting off-target toxicities. Thus, we
have challenged bi-functional MSCs ability to bind GD2-
expressing GBM cells in a cell-to-cell interaction assay
demonstrating that the number of MSC-GBM cell aggre-
gates, collected after interaction, strictly correlated with
both GD2-aboundance on GBM cell lines and the MSCs
capability to interact via GD2 tCAR surface expression. The
bi-functional MSCs selectively bound the highly T98G and
the middle U87MG GD2-expressing lines at a higher extent
than mTRAIL MSCs. Similarly, by challenging bi-
functional MSCs interaction with primary C3c cells, we
found a significantly higher number of aggregates compared
to mTRAIL MSCs. For the A172 GD2-negative line, no
differences in aggregates formation were detected, sug-
gesting that MSCs functionalization by the anti-GD2 AR is
associated with increased and specific binding restricted to
GD2-expressing GBM cells.
The cell-to-cell interaction cytotoxicity assay further
demonstrated that the enhanced binding by bi-functional
MSCs led to a more effective killing activity against GD2-
positive T98G cells, compared to that mediated by mTRAIL
MSCs. As a further confirmation, blocking the GD2-
mediated interaction by bi-functional MSCs incubation with
mice sera against GD2 tCAR restored a killing potential
comparable to that observed with mTRAlL MSCs. These
data demonstrated that GD2 tCAR is able to force the
interaction between bi-functional MSCs and GBM-
expressing GD2 antigen, potentiating the mTRAIL-
mediated cytotoxic effect owing to a selective binding to
GD2-positive GBM cells. Nevertheless, an optimization
within a relevant animal model shall be necessary in order
to better take advantage of the specific GD2 tCAR-binding
capability to the GD2 antigen and to evaluate the ther-
apeutic benefits of bi-functional MSCs carrying both GD2
tCAR and TRAIL.
Targeted delivery of therapeutics has been so far
restricted to lymphocytes based on CAR or bispecific
adaptors [15]. Recently, affinity-based cell targeting has
been also applied to MSCs. Tumor-specific targeting and
retention were achieved by genetic modification of MSCs
with AR against EGFRvIII in GBM [14] and erbB2 in
ovarian cancer [19]. Balyasnikova et al. [14] investigated
the feasibility of expressing a scFv against EGFRvIII on the
surface of MSCs using nucleofection, in order to specifi-
cally target GBM cells expressing EGFRvIII. Similarly,
Komarova et al. [19] created MSCs that express an AR that
binds to erbB2, to explore the possibility of increasing the
number of MSCs in ovarian tumors. Regarding CAR
technology applied to target TRAIL receptors, Kobayashi
et al. [33] generated a CAR with a TRAIL-R1-specific scFv
Fig. 6 Bi-functional MSC-based targeting approach against GBM.
Scheme representing the possible targeted killing mechanism by
locally injected bi-functional MSCs co-expressing the truncated form
of the anti-GD2 CAR (GD2 tCAR) and the membrane-bound TRAIL
(mTRAIL). MSCs surface functionalization with GD2 tCAR could
enforce the in vivo interaction with GD2-expressing GBM cells,
allowing a selective target recognition in such a way to empower
mTRAIL-mediated pro-apoptotic effect
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antibody (TR1-scFv-CAR) transferring it on several cell
types, including human peripheral blood lymphocytes
(PBLs). They report that the TR1-scFv-CAR-expressing
PBLs in vitro killed target cells not only via TR1-mediated
apoptosis but also by CAR signal-induced cytolysis.
However, in these findings there is no evidence of an anti-
cancer molecule delivery by cells simultaneously expres-
sing an AR. Taking inspiration from CAR T cells, for the
first time to our knowledge, we coupled the affinity and the
cytotoxicity by anti-GD2 and TRAIL dual-targeting deliv-
ered using human mesenchymal progenitors. This CAR-
based therapeutic approach holds the promise to achieve
site-specific and prolonged retention of MSCs to the tumor
site, thereby providing an effective delivery of TRAIL pro-
apoptotic molecule in the context of GD2-expressing
cancer.
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